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Abstract 
 Next generation genomic technologies have made a significant contribution to the 
understanding of the genetic architecture of human neurodevelopmental disorders. Copy 
number variants (CNVs) play an important role in the genetics of intellectual disability (ID). 
For many CNVs, and copy number gains in particular, the responsible dosage-sensitive 
gene(s) have been hard to identify. We have collected 18 different interstitial 
microduplications and one microtriplication of Xq25. There were 15 affected individuals 
from 6 different families and 13 singleton cases, 28 affected males in total. The critical 
overlapping region involved the STAG2 gene, which codes for a subunit of the cohesin 
complex that regulates cohesion of sister chromatids and gene transcription. We demonstrate 
that STAG2 is the dosage-sensitive gene within these CNVs, as gains of STAG2 mRNA and 
protein dysregulate disease-relevant neuronal gene networks in cells derived from affected 
individuals. We also show that STAG2 gains result in increased expression of OPHN1, a 
known X-chromosome ID gene. Overall we define a novel cohesinopathy due to copy 
number gain of Xq25 and STAG2 in particular. 
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Introduction 
 Intellectual disability (ID) is a heterogeneous neurodevelopmental disorder (NDD) of 
major societal and personal importance. It is at least 50% genetic and the underlying 
aetiology is complex and highly heterogeneous with thousands of genes and loci likely 
involved. It is estimated that copy number variants (CNVs) are responsible for ~21-25% of 
individuals with ID (1, 2). Determining the clinical significance of CNVs is challenging, in 
particular those involving the X chromosome (3). Chromosome X duplications may lead to 
disease in males due to functional disomy of the duplicated genes (4). Depending on the 
pattern of X chromosome inactivation, heterozygous females can also be variably affected 
(5). CGH detects X-chromosome CNVs in 0-5% of unselected individuals with NDDs (3). Of 
these, duplications of Xq28 including MECP2 are the most frequent (6). In addition, 
duplications of Xq25 encompassing part (7-9) or all (10) of GRIA3, an established XLID (11, 
12) gene, have been associated with clinically variable ID phenotype. More recently, Xq25 
duplications involving THOC2, XIAP, STAG2 or SH2D1A, which are located distal to GRIA3, 
have been implicated in ID (10, 13-15). However, the dosage-sensitive gene or genes driving 
the disease phenotype in affected individuals has remained elusive. Here we present data 
from systematic and in-depth clinical and molecular studies of 28 affected males (15 from six 
unrelated families and 13 singleton cases) harbouring Xq25 microduplications and one case 
of a triplication showing that STAG2 is the dosage-sensitive gene in the affected individuals. 
Our results define a novel cohesinopathy due to copy number gain of Xq25 and STAG2 in 
particular.  
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Results 
STAG2 copy number gains are implicated in intellectual disability and behavioural 
problems 
 Initially we identified Xq25 microduplications and one microtriplication in six 
unrelated index males with ID and various additional clinical features through genome-wide 
array comparative hybridization (aCGH) (families NSW, SA1 and SA2) and X-chromosome 
exome sequencing as previously described (16-18) (families D57, D166 and L70). The 
duplicated regions varied from 202 kb to 746 kb in length and contained THOC2-XIAP-
STAG2, XIAP-STAG2 or partial XIAP and STAG2. The triplicated region contained XIAP and 
STAG2 (Fig. 1A). We confirmed the copy number gains by qPCR, high resolution aCGH and 
fluorescent in situ hybridization (FISH), and where available, tested their segregation in 
extended pedigrees (Fig. 2 and data available on request). All procedures followed were in 
accordance with the ethical standards of the appropriate institutional Human Research Ethics 
Committees and proper informed consent was obtained. 
 Subsequently we evaluated 27 000 males with neurodevelopmental delay and/or 
congenital anomalies (and 6 459 male controls) referred for clinical aCGH testing and 
identified an additional 13 sporadic singleton cases with a duplication encompassing STAG2. 
In addition to STAG2, GRIA3 was duplicated in one, THOC2 in two, XIAP in six and 
SH2D1A in one individual (Fig. 1B; Signature Genomics and Baylor College of Medicine). 
In addition, three individuals with only STAG2 and one individual with STAG2-SH2D1A and 
partial TENM1 duplication were identified in the DECIPHER database (Fig. 1B). Taken 
together, we show that in all affected individuals the critical region contains STAG2. This led 
us to hypothesize that STAG2 gains might play a role in abnormal development and that 
STAG2 is the disease-relevant gene in Xq25 duplications (7-10, 13, 14), and not GRIA3 as 
previously speculated (7, 10). To test our hypothesis of the importance of STAG2 dosage for 
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normal neuronal development, we clinically evaluated all affected individuals from the initial 
six families and compared them with previously published cases. We also performed STAG2 
expression analysis at the mRNA and protein level using cells derived from affected 
individuals.  
 The clinical details of our and published cases with Xq25 microduplications and their 
family members (total 43; males 33) are presented in Table 1 and Table S1. Clinical 
description of the SA1 family with Xq25 triplication is highlighted in Table S1. Photographs 
of the affected individuals are shown in Fig. 2. We have also reviewed the clinical findings of 
18 males from the literature together with the DECIPHER cases 250183 and 270242 (7, 10, 
13-15, 19), who all carry an Xq25 duplication encompassing STAG2. All males with Xq25 
duplications presented with some degree of ID, mostly mild-moderate ID. Of the carrier 
females (n=10), one had mild ID, six were described as having borderline ID or delays, and 
the remaining three had normal cognitive function. Behavioural problems, such as anxiety, 
hyperactivity and aggressive behaviour were noted in 68% (19/28) of all affected males. 
Autism spectrum disorder was reported in four males. Short stature was noted in 21% (6/28) 
of cases for whom information was available. Head circumference was typically in the 
normal range. Seizures were only noted in 32% (10/31) males, excepting one female. Brain 
imaging was performed in ten individuals; four were reported as normal and among the six 
with abnormalities, cerebellar vermis hypoplasia were noted in four, a thin corpus callosum 
in three and prominent subarachnoid spaces in two. Facial features were not clearly 
documented in all cases, however there is evidence of a subtle, but consistent phenotype 
including malar flatness, full lips and prognathia was present in 23/27, 15/26 and 16/26, 
respectively. Recently clinical information and photographs of six affected children carrying 
STAG2 duplications has been reported (19) and many of the features overlap with adult faces 
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shown here, although the thin arched eyebrows and facial hypotonia are less apparent with 
age.  
 The affected male of family SA1 who carries a triplication of XIAP and STAG2 had a 
more severe clinical phenotype compared to individuals with Xq25 duplication. He presented 
with severe ID, stereotypies, obsessive-compulsive behaviour, anxiety and aggressive 
outbursts. He was dysmorphic, with a broad forehead, frontal bossing, small posteriorly-
rotated low-set ears, long nose, smooth philtrum, wide spaced teeth, gum hypertrophy, facial 
hypotonia, short distal phalanges of fingers and 2-3 toes syndactyly. He also had 
hypermetropia, tight Achilles tendons and valgus foot deformity. Imaging demonstrated 
cone-shaped epiphyses of toes 2-4 and mild cerebral ventricular enlargement with prominent 
subarachnoid spaces. The mother, who has 4 copies of the region, had slightly skewed X-
inactivation (85:15) and had borderline ID and schizophrenia. 
 
STAG2 and XIAP but not THOC2 protein levels reflect their copy number gains in 
patient-derived cells  
 To identify the dosage-sensitive gene(s), we assayed STAG2, XIAP and THOC2 
mRNA and protein expression in lymphoblastoid cells (immortalised B-lymphocytes, LCLs) 
derived from one affected individual of each of the NSW, SA1, D57, and L70 families and 
five male controls. Compared to controls, STAG2 mRNA expression was increased in all four 
LCLs derived from the affected individuals, while XIAP expression was higher in LCLs from 
the NSW, SA1 and D57 families, and THOC2 expression was elevated in LCLs from the 
NSW and D57 families (Fig. S1). These results showed that the expression of all duplicated 
and triplicated genes is significantly increased reflecting the copy number gains and that 
partial duplication of XIAP present in family L70 did not disrupt XIAP gene expression (Fig. 
S1). Subsequent western blot analysis of cell lysates revealed increased amounts of STAG2 
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8 
and XIAP protein in affected males from the NSW, SA1, and D57 families and only an 
elevated STAG2 level in the affected male from family L70 (Fig. 3). In contrast, THOC2 
protein levels remained unchanged in all LCLs, including the NSW and D57 families, which 
carry THOC2 duplications (Fig. 3). This suggests that normal THOC2 protein levels in these 
LCLs are maintained by other means. We have evidence that post-translational regulation, 
potentially through proteasome-mediated degradation given THOC2 has been shown to be 
ubiquitylated (20), might be involved (21). Taken together, these results suggest that THOC2 
is not implicated in the phenotype associated with STAG2 Xq25 copy number gains. XIAP 
involvement cannot be fully excluded, but it is less likely given the individual from family 
L70 who has normal XIAP protein levels (see Fig. 3B). Therefore, we hypothesized that copy 
number gains of STAG2 alone could be responsible for the phenotype. 
 
Transcriptome is dysregulated in patient-derived cells 
 To test our hypothesis we performed transcriptome analysis on LCL-derived mRNA 
of one affected male from the NSW, D57, SA1 and L70 families and five male controls. We 
and others have demonstrated that RNA-seq analysis on patient-derived cells can provide 
meaningful results for the understanding of normal brain function and development (22, 23). 
RNA-seq analyses showed that in comparison to control LCLs, 214 genes were significantly 
dysregulated (126 up- and 88 down-regulated; FDR < 0.1) in the four LCLs with Xq25 
duplication or triplication (Table S2). We validated our RNA-seq analyses by testing a set of 
dysregulated genes using real-time RT-qPCR (Fig. 4, 5A). These included: SLCO4C1 (Log2 
fold change -1.5, P < 0.01), encoding solute carrier organic anion transporter family member 
4C1, a member of the organic anion transporter (OATP) family, which is involved in 
membrane transport of bile acids, conjugated steroids, thyroid hormone, eicosanoids, 
peptides, and numerous drugs in many tissues (24); CMTM7 (Log2 fold change 3.4, P < 
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4.510-6), encoding CKLF-like marvel transmembrane domain-containing 7 the exact 
function of which is unknown (25); and OPHN1 (Log2 fold change 4.1, P < 310-5), encoding 
a Rho-GTPase-activating protein, important for dendritic morphogenesis and synaptic 
function (Fig. 5A). Compared with the controls, LCLs with duplications showed significantly 
higher OPHN1 expression, which was even higher in SA1 LCLs with a XIAP-STAG2 
triplication (Fig. 5A). OPHN1 is a known disease gene, whose loss-of-function mutations are 
responsible for XLID with cerebellar hypoplasia and distinctive facial dysmorphisms. To 
investigate whether increased OPHN1 expression results from higher cellular levels of 
STAG2, XIAP or both, we measured the levels of OPHN1 mRNA in HEK293T cells 
overexpressing epitope-tagged STAG2, XIAP or vector only. Significant increase in OPHN1 
mRNA was observed in STAG2, but not XIAP overexpressing HEK293T cells (Fig. 5B). 
These results suggest that the clinical phenotype associated with Xq25 gains could at least 
partly be due to OPHN1 overexpression. 
 
Copy number gains dysregulate disease-relevant neuronal gene networks in patient-
derived cells 
 To determine the biological and functional relevance of the significantly dysregulated 
genes in LCLs from the affected males with Xq25 copy number gains, we performed 
computational Ingenuity Pathway Analysis using the 214 significantly (FDR < 0.1) 
differentially expressed genes (Table S2). This analysis identified networks of genes with 
functions in development of neurons (P<0.0008), neuron viability (P<0.002), seizures 
(P<0.0002), disorder of basal ganglia (P<0.001), neuronal cell death (P<0.0003), formation of 
forebrain (P<0.001), and movement disorders (P<0.0001); neurological disease, cell-to-cell 
signalling, and interaction and inflammatory response (network 3) and neurological disease, 
organismal injury and abnormalities (network 4) (Fig. S2). Independent analysis using WEB-
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10 
based GEne SeT AnaLysis Toolkit (26), the differentially-expressed genes were grouped into 
categories such as global developmental delay (17 genes), cognitive impairment (33 genes) 
and encephalopathy (4 genes). Finally, we observed several other genes with known 
involvement in neuronal processes among the differentially expressed genes. Mutations in 
many of these are associated with ID, developmental delay, epilepsy or neuropsychiatric 
disorders (e.g. COL4A2, GPR98, TSPAN7 or TUBB2B and 2A, Tables S2 and S3). Taken 
together, these results reinforce deleterious molecular and likely also cellular consequences of 
increased dosage of STAG2. 
 
Discussion 
 We have identified 28 affected males (15 from our six unrelated families and 13 
others; excluding cases from the DECIPHER database) with copy number gains at Xq25 that 
are associated with ID, behavioural problems, seizures, malar flatness and prognathism. The 
copy number gains involved one or more genes: STAG2 (28 cases), XIAP (17 cases), THOC2 
(12 cases) and GRIA3 (1 case), which are all expressed in the human brain (27). One of the 
rarely duplicated genes is GRIA3, which encodes glutamate receptor ionotropic AMPA 
subunit 3. Loss-of-function of GRIA3 due to gene truncation by a chromosome translocation, 
missense variants, partial tandem duplication or a microduplication located 874 kb upstream 
of GRIA3 has been linked to bipolar affective disorder and XLID (8, 11, 12, 28, 29). THOC2 
protein functions as a component of the mRNA transcription/export (TREX) complex (30, 
31). TREX transiently-binds the capped, spliced and processed mRNAs, allowing binding of 
additional proteins that facilitate export of mRNA from the nucleus to the cytoplasm (32). 
While our data show that THOC2 loss-of-function variants cause XLID (21), the results of 
this study show that increased genomic dosage of THOC2 is probably not deleterious. Firstly, 
THOC2 is not duplicated in 16/28 affected males and secondly, THOC2 protein level is not 
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11 
increased in the affected individuals with THOC2 duplications. XIAP (X-linked inhibitor of 
Apoptosis), also called BIRC4, is a member of Inhibitors of Apoptosis (IAPs) family of 
proteins that, besides its major role in apoptotic regulation, performs diverse biological 
functions, mainly through its E3 ubiquitin ligase activity (33). XIAP has a neuroprotective 
role, particularly in response to injury to the developing brain (34, 35), its expression is 
reduced in Huntington disease brain tissues (36) and loss-of-function mutations cause X-
linked lymphoproliferative syndrome (37). XIAP expression is affected in all but one Xq25 
duplication cases we tested, that of family L70, and in many other cases XIAP was not even 
involved in the duplicated region. Based on our aggregate clinical, genetic, molecular and 
mRNA expression studies we conclude that STAG2 is the dosage-sensitive gene in Xq25 
microduplications. 
 Detailed clinical assessment of the newly identified patients with Xq25 duplications 
as part of our study along with those reported earlier (Table 1 and S1) reinforces previously 
suggested phenotypic hallmarks (7, 10, 13-15, 19). The question whether the individuals with 
different size Xq25 duplication and as such gene content are clinically different is highly 
relevant. While deriving firm conclusions will require more patients and extensive re-
evaluation of clinical data, patients with STAG2 gene only duplications appear to be generally 
less severely affected. 
 STAG2 codes for a subunit of the cohesin complex that is essential for many cellular 
functions such as sister chromatid cohesion and segregation (canonical roles) and 
maintenance of chromatin architecture, DNA replication, DNA repair and transcriptional 
regulation (non-canonical roles)  (38). Interestingly and very much in line with our results, 
cohesin also has multiple transcriptional roles and is tightly regulated. Minor changes in 
cohesin activity cause the neurodevelopmental disorder Cornelia de Lange Syndrome (CdLS) 
that presents with phenotypic variability, including ID, facial dysmorphism, growth delay, 
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12 
limb abnormalities and other phenotypes (39, 40). Notably duplication involving the SMC1A 
gene, which encodes a cohesin complex subunit is shown to be associated with growth 
retardation, muscular skeletal abnormalities and ID, all features seen in other cohesin 
disorders, CdLS is one such disorder (41). Several studies indicate that cohesin regulates 
transcription by facilitating insulator and enhancer-promoter looping, and by controlling the 
transition of promoter-proximal paused Pol II to efficient elongation (42). STAG2, or in some 
cases STAG1 which is mutually exclusive with STAG2, is the only cohesin subunit 
interacting directly with the zinc finger DNA-binding protein CTCF. This interaction bridges 
cohesin with CTCF, which is required for cohesin-dependent insulation activity (43) and has 
also been directly and indirectly implicated in ID (44, 45). Recently, deleterious variants of 
STAG1 have been reported in two individuals with ID and in one of them cognitive 
impairment is accompanied by behavioural problems including autism, anxiety, mood 
instability and aggressive outbursts (46, 47). Cohesin also interacts with the Mediator 
complex, a transcriptional coactivator and STAG1, which physically interacts with the 
pluripotency transcription factor Nanog (48). Furthermore, gene mutations in core and 
regulatory cohesin proteins have been identified in a wide range of cancers, where STAG2 
was the most frequently mutated gene (49). Whereas many cancers were caused by STAG2 
inactivating mutations that caused chromosomal instability, some cancer types with normal 
karyotype could only be explained by dysregulation of gene expression, and STAG2 
mutations can be involved. So far no STAG2 loss-of-function or point mutations have been 
identified in individuals with NDD and more specifically in cohesin associated syndromes 
like CdLS (50), apart from 1 de novo missense mutation picked up by the recent DDD UK 
study (51). Taken together, tight regulation of cohesin core subunits and regulatory genes is 
essential for normal cell division and gene expression, and their dysregulation results in 
related NDDs termed cohesinopathies, although affected individuals have no overt defects in 
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13 
chromosome segregation, instead they have altered gene expression in hundreds of genes, 
suggesting that the pathology of these disorders is independent of cohesin’s role in sister 
chromatid cohesion. Given our results showing that many of the dysregulated genes of the 
affected individuals with STAG2 duplications are expressed in the brain and have critical 
roles in the development of the nervous system (Tables S2 and S3 and Fig. S2), we can 
speculate that STAG2 increased expression leads to another form of cohesinopathy. 
Using RNA-Seq we identified several differentially expressed genes in the 
lymphoblasts of the patients with Xq25 copy number gains. Among the most significantly 
dysregulated genes were multiple gens known to cause, when mutated, various neurological 
disorders with ID, e.g. TUBB2B (OMIM #610031) and 2A (OMIM #615763), COL4A2 
(OMIM #614483), GPR98 (OMIM #605472), TSPAN7 (OMIM #300210) or OPHN1 (OMIM 
#300486). We followed up on one of these, OPHN1, which we discovered to be up-regulated 
in LCLs from affected individuals of the NSW, D57, L70 and SA1 families. OPHN1 is 
highly expressed in the brain (52) and important for regulation of dendritic morphogenesis 
and synaptic plasticity (52-54). Loss-of-function mutations in OPHN1 are responsible for 
syndromic XLID with cerebellar hypoplasia, variable epilepsy and distinctive facial 
dysmorphisms (55). In contrast, individuals who carry a duplication including OPHN1 had a 
different and distinctive phenotype. A maternally inherited Xq12q13.1 duplication 
encompassing OPHN1, YIPF6 and STARD8 has been reported in a male with severe ID, 
language impairment and apparent dysmorphisms (56). A duplication encompassing OPHN1, 
YIPF6, STARD8, EFNB1 and PJA1 has been reported in a male with speech delay, 
developmental delay and facial dysmorphic features (57) and a large duplication (Xq12q13.3) 
including OPHN1 has been reported in severely affected male siblings with global 
developmental delay and autism (58). These data are consistent with a hypothesis that higher 
OPHN1 expression in individuals carrying STAG2 copy number gains may contribute to their 
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clinical presentations. Furthermore, OPHN1 overexpression in rat pyramidal neurons was 
shown to enhance AMPA receptor-mediated transmission, and significantly increased spine 
size without altering the spine density (53). While perturbed STAG2-mediated OPHN1 
signalling likely contributes to the cognitive impairment in individuals with Xq25 copy 
number gains, contributions of the other likely-involved genes (see above and Table S2 and 
S3) also needs to be considered and investigated in order to determine the most likely-drivers 
of the clinical phenotype. 
Broad diagnostic and research application of new genomic technologies has 
dramatically accelerated the discovery of microdeletions and microduplications associated 
with neurodevelopmental disorders (59). There are now many examples of dosage-sensitive 
loci showing both deletion and duplication phenotypes, with the deletion phenotypes 
typically more severe than the duplication phenotypes (60-62). However, the identification of 
the dosage-sensitive gene(s) has been challenging. Our clinical, genetic and molecular data 
provide strong evidence that STAG2 is the dosage sensitive gene that is responsible for a 
novel cohesinopathy with ID, behavioural problems and other clinical presentations seen with 
Xq25 copy number gains.  
 
Materials and Methods 
Generation and maintenance of lymphoblastoid cell lines (LCLs) 
The Epstein-Barr virus (EBV) immortalised B-cell lines (lymphoblastoid cell lines) were 
established from peripheral blood lymphocytes of patients and controls following published 
method (63).  Briefly, lymphocytes were isolated from 5-10 ml of whole blood using 
lymphoprep reagent following manufacturer's protocol (GE Life Sciences, Australia) and 
cultured for a period of two weeks in RPMI 1640 (Sigma-Aldrich, NSW, Australia) 
supplemented with 20% fetal calf sera (FCS), 2mM L-Glutamine and 0.017 mg/ml 
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benzylpenicillin in the presence of EBV and 0.001 mg/ml Cyclosporin A (Sigma). Once 
established, the LCLs were maintained in RPMI 1640 supplemented with 10% FCS, 2mM L-
Glutamine and 0.017 mg/ml benzylpenicillin at the conditions 37°C with 5% CO2. 
 
RNA-Seq and RT-qPCR analyses 
Total RNA was isolated from LCLs derived from one affected individual of NSW, D57, SA1 
and L70 and five control LCLs using Quick RNeasy mini kit (Qiagen, VIC, Australia). The 
cDNA libraries were prepared with the Illumina TruSeq LT protocol using 2g RNA per 
sample and sequenced on the Illumina HiSeq 2000 (Illumina, San Diego, CA, USA). 
Approximately 80 million pair-end reads per sample were mapped to the Hg19 build of the 
human genome using Tophat (version 2.0.9). HTSeq (version 0.5.4p5) was used to generate 
the raw counts. Differentially expressed genes (FDR < 0.1) were identified by comparing the 
patients and controls using edgeR package (64). Quantitative RT-qPCR was used for 
validating the differentially-regulated genes in LCLs from affected individuals using mRNA-
specific primers or Taqman probes (Life Technologies, VIC, Australia) (Table S4). Total 
RNA reverse transcribed with SuperScript III reverse transcriptase (Life Technologies) was 
used for assaying the levels of OPHN1 expression by Taqman approach. RNaseP was used as 
a housekeeping gene to normalise OPHN1 expression. SCLO4C1 and CMTM7 expression 
was assayed by RT-qPCR using SYBR Green master mix (Bio-Rad, NSW, Australia) using 
primers listed in Table S4. HPRT1 was used as a housekeeping gene for normalising 
SCLO4C1 and CMTM7 expression. 
 
XIAP and STAG2 expression plasmids 
pEGFP-STAG2 expression plasmid was purchased from Addgene (number 31972). pDsRed-
monomer-C1-XIAP expression plasmid was generated by cloning human XIAP coding 
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sequence (PCR amplified from brain cDNA with hXIAP-EcoRI-F and hXIAP-BamHI-R 
primers, Table S4) in-frame with the RFP coding sequence at EcoRI-BamHI sites of pDsRed-
monomer-C1. Sequence was confirmed by Sanger sequencing using the BigDye Terminator 
v3.1 chemistry (Life technologies).  
 
Western blotting 
Total LCL lysates were prepared in 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 1 mM EDTA, 
50 mM NaF, 0.1 mM Na3VO4, 1 protease inhibitors (Roche, NSW, Australia) and 1% 
Triton-X-100, resolved on 3-8% Tris-Acetate (THOC2; Life Technologies) or 7% SDS-
PAGE (65) (XIAP or STAG2) gels, transferred to nitrocellulose membranes and probed with 
rabbit anti-XIAP (Cell Signaling, QLD, Australia), anti-STAG2 (Cell Signaling) or anti-
THOC2 (Bethyl Laboratories, Montgomery, TX, USA) primary antibodies followed by 
donkey anti-rabbit-IgG-HRP secondary anybodies (Dako, VIC, Australia). Blots were probed 
with rabbit anti--tubulin (Abcam, VIC, Australia) to control for even loading of protein 
amounts. Proteins were detected by Enhanced Chemiluminescence reagents (GE Life 
Sciences). 
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Figure legends 
Figure 1. Summary of Xq25 copy number gains. (A) Detailed description of five 
microduplications and a microtriplication of Xq25. Duplications and triplications were 
identified by CGH array (NSW, SA1 and SA2) or X-chromosome exome sequencing (D57, 
D166 and L70). Gene dosage was experimentally validated using Taqman assays (probe 
locations shown as blue lines above the XIAP and STAG2 genes). STAG2 is common to all 
copy number gains. gDNA, genomic DNA. 2×, duplication; 3×, triplication. (B) Overview of 
our and published Xq25 copy number gains. Note that the shortest region of overlap includes 
STAG2. Positions are according to UCSC hg19. Xq25 carrying a partial GRIA3 duplication in 
an individual with autism spectrum disorder (9) and an ID-associated 5.02 Mb duplication 
carrying a number of genes (10) are not shown.   
 
Figure 2. Pedigrees of families with Xq25 copy number gains. Pedigrees of six ID 
families with microduplications or a microtriplication at Xq25 including THOC2, XIAP 
and/or STAG2. * = microduplication/microtriplication carrier, wt = does not carry 
microduplication/microtriplication. Front and side facial views of the affected individuals are 
shown (photographs published with consent). 
 
Figure 3. Endogenous XIAP and STAG2 but not THOC2 protein levels are increased in 
Xq25 copy number gains. Western blot analysis of THOC2, XIAP and STAG2 proteins 
using affected individual (Panel A: SA1, NSW, D57 and Panel B: L70) and control LCLs. 
While levels of THOC2 were unaltered in the affected LCLs with THOC2 duplication (NSW, 
D57), increased XIAP and STAG2 levels reflected their genomic copy number gains (SA1, 
NSW, D57, L70). SA1 mother (with four copies of XIAP-STAG2; Lane 1, Panel A) of 
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27 
affected male (with three copies of XIAP-STAG2; Lane 2, Panel A) had XIAP and STAG2 
protein comparable to the control LCLs.  
 
Figure 4. Xq25 copy number gains and gene dysregulation. The differentially-expressed 
genes were identified by RNA-Seq analysis of total RNA extracted from LCLs derived from 
one affected individual of NSW, D57, SA1 and L70 and five control LCLs (see Materials and 
Methods). Total RNA reverse transcribed with SuperScript III reverse transcriptase was used 
for validating the SCLO4C1 (A) and CMTM7 (B). SCLO4C1 and CMTM7 expression was 
assayed by RT-qPCR using SYBR Green master mix and primer pairs listed in Table S4 and 
normalised to expression of HPRT1 housekeeping gene. T-X-S, THOC2-XIAP-STAG2 
 
Figure 5. OPHN1 mRNA levels are significantly increased in cells expressing high levels 
of STAG2 protein. (A) RT-qPCR assay showing significantly higher OPHN1 expression in 
LCLs from the affected males with STAG2 copy number gains (P < 0.002). OPHN1 
expression was assayed by RT-qPCR using Taqman approach (Table S4) and normalised to 
the housekeeping RNaseP gene expression. T-X-S, THOC2-XIAP-STAG2. (B) OPHN1 
expression is induced in HEK293T cells overexpressing recombinant epitope-tagged STAG2 
(EGFP-STAG2 vs pEGFP-C1, P < 0.03) but not in cells overexpressing the XIAP protein. 
Cells were transfected with the plasmids as shown and harvested 24hr later. One-half of the 
cells were western blotted (66) with mouse anti-EGFP (Roche) or rabbit anti-RFP (Life 
technologies) and appropriate HRP-conjugated secondary antibodies to confirm EGFP-
STAG2, EGFP, dsRFP-XIAP and dsRFP expression (Fig. S3). Probing for -tubulin was 
used to confirm even loading of protein samples. The other half was used for extracting total 
RNA that was used for RT-qPCR assay to determine OPHN1 mRNA levels using a Taqman 
approach.  
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28 
Table 1. Summary of typical clinical features in affected males. 
 
Typical clinical features Affected/Accessible data (%) 
Duplications and a triplication n=33 
ID 
 
borderline or not specified type 3/33 (9) 
mild/mild-moderate 16/33 (48) 
moderate 12/33 (36) 
severe 2/33 (6) 
autism spectrum disorder 4/15 (27) 
seizures 10/31 (32) 
behavior problems 19/28 (68) 
malar flatness 23/27 (85) 
thick vermillion 15/26 (58) 
facial hypotonia 16/27 (59) 
prognathism 16/26 (62) 
heavy eyebrows 7/17 (41) 
head circumference (OFC) 
 
normal 22/27 (81) 
OFC < P10 1/27 (4) 
OFC > P90 4/27 (15) 
height 
 
normal  19/28 (68) 
short stature 6/28 (21) 
tall stature  3/28 (11) 
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